Piotr Najgebauer

Piotr Najgebauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piotr Najgebauer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interaction of ibotenic acid with selected small nanographene oxide (GO) models

    by Piotr Najgebauer, Monika Staś-Bobis, Teobald Kupka


  • PRZEGLĄD TOKSYN WYSTĘPUJĄCYCH W GRZYBACH

    by Piotr Najgenauer, Monika Staś-Bobiś, Teobald Kupka

    Mushroom toxins are diversified range of toxic chemical compounds. They vary significantly not only in structures but also in toxicity and level of risk they pose. Some, such as amatoxins, are lethal, while others, like psilocybin are intentionally used as hallucinogens. Certain toxins, such as coprine, may be harmful only under specific conditions. Despite centuries of awareness regarding the potential toxicity of mushrooms, intoxications resulting from mushroom consumption still occur. In this review, our aim is to provide an overview of the mushroom toxins. The first part of this work presents the overview of mushroom toxins, detailing their basic features such as structures and toxicity, along with mushroom species in which they occur. In the second part of this article, we describe selected toxins grouped by their toxicity, into five categories: neurotoxins, hepatotoxins, cytotoxins, nephrotoxins and myostatins.


  • Open Access

    Imidazole-amino acids. Conformational switch under tautomer and pH change

    by Monika Staś, Piotr Najgebauer, Dawid Siodłak

    Replacement of the main chain peptide bond by imidazole ring seems to be a promising tool for the peptide-based drug design, due to the specific prototropic tautomeric as well as amphoteric properties. In this study, we present that both tautomer and pH change can cause a conformational switch of the studied residues of alanine (1–4) and dehydroalanine (5–8) with the C-terminal peptide group replaced by imidazole. The DFT methods are applied and an environment of increasing polarity is simulated. The conformational maps (Ramachandram diagrams) are presented and the stability of possible conformations is discussed. The neutral forms, tautomers τ (1) and π (2), adapt the conformations αRτ (φ, ψ = − 75°, − 114°) and C7eq (φ, ψ = − 75°, 66°), respectively. Their torsion angles ψ differ by about 180°, which results in a considerable impact on the peptide chain conformation. The cation form (3) adapts both these conformations, whereas the anion analogue (4) prefers the conformations C5 (φ, ψ = − 165°, − 178°) and β2 (φ, ψ ~ − 165°, − 3°). Dehydroamino acid analogues, the tautomers τ (5) and π (6) as well as the anion form (8), have a strong tendency toward the conformations β2 (φ, ψ = − 179°, 0°) and C5 (φ, ψ = − 180°, 180°). The preferences of the protonated imidazolium form (7) depend on the environment. The imidazole ring, acting as a donor or acceptor of the hydrogen bonds created within the studied residues, has a profound effect on the type of conformation.


  • Open Access

    Are peptide drugs the future of medicine?

    by Maciej Miliński, Piotr Najgebauer, Radosław Balwierz, Urszula Skotnicka-Graca, Monika Staś